ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 02 May 2019
Last Updated on 02 May 2019
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has not recommended listing febuxostat on the Medication Assistance Fund (MAF) for treating chronic hyperuricaemia in adults with gout because of unacceptable cost-effectiveness compared with alternative treatments at the price proposed by the manufacturer.


Febuxostat for chronic hyperuricaemia in adults with gout (2 May 2019) Febuxostat Plain English Summary (2 May 2019)